Hyperuricemia aggravates acute pancreatitis through CNR1-mediated inflammatory signaling and gut-pancreas axis dysregulation: a multi-omics and clinical study Authors: Jiayi Wang, Zehong Qi, Yujiao Zhu, Daolin Tang, Nian Wang, Jingbo Li Published: 2026 ABSTRACT Hyperuricemia (HUA) is implicated in various metabolic and inflammatory diseases. Its role in the pathogenesis of acute pancreatitis (AP), particularly in gut-pancreas crosstalk and the underlying molecular mechanisms, remains poorly understood. This study integrates clinical epidemiology (UK Biobank cohort and the Third Xiangya Hospital cohort), (L-arginine-induced AP mouse models), and multi-omics analyses (RNA sequencing, fecal metabolomics, and gut microbiome profiling) to elucidate the role and mechanistic pathways of uric acid in the onset and severity of AP. Key molecular targets and regulatory relationships identified were further validated via in vitro cellular experiments using pancreatic acinar cells and bone marrow-derived macrophages. In the UK Biobank cohort, over a median follow-up period of 13.69 years, participants in the highest uric acid quartile exhibited a significantly increased risk of developing AP compared to the lowest quartile (hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.10–1.43). In the Third Xiangya Hospital cohort, AP patients with elevated serum uric acid levels exhibited more severe symptoms. The combination of uric acid and calcium demonstrated superior predictive capability for AP severity (AUC 0.9504). In the preclinical models, HUA aggravated AP progression, as demonstrated by increased pancreatic histopathological damage, elevated serum amylase levels, multi-organ dysfunction, and higher mortality. Mechanistically, HUA exacerbated AP in mice via cannabinoid receptor 1 (CNR1)-mediated retrograde endocannabinoid signaling, which enhanced macrophage-derived IL-1β and IL-6 production. Metabolomics revealed that the gut-derived flavonoid maesopsin exerted a protective anti-inflammatory effect in the context of HUA-augmented AP. Additionally, Limosilactobacillus genus, particularly Limosilactobacillus reuteri D, was enriched in the HUA + AP group and strongly associated with maesopsin levels. Uric acid exacerbates AP progression via CNR1 driven inflammatory signaling and modulates gut microbiota composition and metabolism. Serum uric acid, especially when combined with calcium, may be integrated into routine clinical assessment for AP risk stratification and severity prediction, while CNR1 and gut microbiota-related targets provided potential directions for the developing adjunctive therapies for HUA-associated AP.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54458-4. Introduction Acute pancreatitis (AP) is an inflammatory condition of the pancreas, primarily triggered by the premature activation of pancreatic enzymes, leading to autodigestion, local tissue injury, and even systemic inflammatory responses1. AP is a leading cause of gastrointestinal-related hospitalizations in the United States, with over 288,000 cases reported annually, and its global incidence continues to rise2,3. Gallstones and alcohol consumption remain the predominant etiological factors; however, the global rise in obesity and the associated increase in gallstone formation may be contributing to the growing burden of AP worldwide4,5. The revised Atlanta Classification (2012) stratifies AP into three clinical categories: mild (MAP), moderately severe (MSAP), and severe (SAP)6. Approximately 20% of patients progress to MSAP or SAP, which are associated with increased need for intensive care and elevated mortality rates7. These trends highlight the urgent need to identify modifiable risk factors that influence both the onset and severity of AP to mitigate its clinical and economic burden. Uric acid, the final metabolite of purine degradation, plays a dual role in human health. Hyperuricemia (HUA), defined as serum uric acid levels > 7.0 mg/dL (416.0 µmol/L) in males and > 6.0 mg/dL (357.0 µmol/L) in females, can result from dietary excess, obesity, alcohol intake, and certain medications8,9. Traditionally associated with gout, HUA has also been epidemiologically linked to cardiovascular and renal disorders, neurodegenerative diseases, metabolic syndrome, and various cancers10–14. Mechanistically, uric acid exerts both antioxidant and pro-oxidant effects, engages in immune modulation, regulates nitric oxide bioavailability, and is involved in inflammatory and aging-related processes8,13,15. A recent study has reported elevated serum uric acid levels in patients with AP compared to healthy controls16. Despite these preliminary observational findings, the specific biological role of uric acid in AP pathogenesis has not been fully characterized, and its potential as a modifiable risk factor or clinical biomarker for AP remains to be systematically validated. At physiological concentrations, uric acid can scavenge reactive oxygen species (ROS), thereby exerting antioxidant effects and limiting oxidative stress15,17,18. However, at supraphysiological levels, uric acid may adopt a pro-oxidant and pro-inflammatory role, amplifying oxidative damage and immune activation19–21. These mechanisms are particularly relevant in SAP, where exaggerated systemic inflammation contributes to organ failure and increased mortality22,23. Nevertheless, the specific relationship between uric acid levels and AP severity is not fully understood. Emerging evidence implicates a bidirectional interaction between uric acid homeostasis and the gut microbiota. HUA can reshape gut microbial communities, while gut dysbiosis impairs uric acid excretion and promotes systemic inflammation24–26. This relationship may have particular relevance in AP, where gut barrier dysfunction facilitates microbial translocation, contributing to pancreatic necrosis, infection, and multi-organ dysfunction27. Notably, the regulatory role of the gut-pancreas axis in HUA-exacerbated pancreatic injury has yet to be fully elucidated. There is a critical gap in integrated research that combines multi-omics profiling and preclinical experimental validation to unravel the crosstalk between host signaling pathways, gut microbial composition, and metabolic alterations in this pathological process. Although hyperuricemia has been epidemiologically associated with acute pancreatitis, the specific molecular mechanisms by which elevated uric acid modulates the onset and severity of AP remain poorly defined. In this study, we aimed to (1) elucidate the longitudinal relationship between serum uric acid levels and the AP incident; (2) evaluate the relationship between serum uric acid and AP severity; and (3) investigate the mechanistic contribution of gut microbiota and metabolic alterations to uric acid-mediated pancreatic injury. Materials and methods Human study Study design and participants The prospective cohort study was conducted using data from the UK Biobank, an ongoing large population-based cohort study, in which over 500,000 individuals aged 40–59 years at 22 assessment centers across Wales, England, and Scotland from 2006 to 201028. After excluding participants with AP at baseline or with missing data on uric acid, a total of 467,859 individuals were eligible and included in the analysis for the association of uric acid with incident AP. The ethical approval for the UK Biobank (REC reference: 21/NW/0157) was provided by the North West-Haydock Research Ethics Committee, U.K. Written informed consent was obtained from the participants when they were recruited in the UK Biobank, and the detailed information can be found in the UK Biobank (https://www.ukbiobank.ac.uk/). A matched case-control study using data from the Third Xiangya Hospital of Central South University aims to study the relationship between uric acid and the severity of AP. Between January 2020 and June 2023, a total of 176 individuals with SAP and complete uric acid data were enrolled in this study; meanwhile, the data of 176 sex- and age-matched AP patients were collected. This part of the study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by The Third Xiangya Hospital of Central South University (REC reference: 25624). The requirement for informed consent was waived by the ethics committee due to the retrospective nature of the study and all the data being anonymized. Measurement of uric acid UK Biobank has collected peripheral venous blood samples from all participants with an available sample at baseline, and the detailed procedure for blood processing and biochemical analysis has been described elsewhere29. Specifically, uric acid was measured by uricase PAP analysis on a Beckman Coulter AU5800. One set of peripheral venous blood samples was collected per patient within 24 h of admission at the Third Xiangya Hospital. The samples were then taken to the Clinical Laboratory Unit of the Third Xiangya Hospital and tested for uric acid. Ascertainment of acute pancreatitis The source of AP in the UK Biobank was ascertained from hospital admissions data, self-reported diagnoses, death registers, and primary care records. Individuals with AP were identified in hospital admissions data using the International Classification of Diseases-9 (ICD-9) codes (5770) and ICD-10 codes (K85). Similarly, the diagnosis of AP at the Third Xiangya Hospital was based on the ICD-9 and ICD-10 codes. The three clinical categories of AP were mentioned above. Covariates In the UK Biobank, the following covariates were included in this analysis. The sociodemographic factors included age (continuous), sex (female or male), ethnic background (white or non-white), education level (with or without college degree), Townsend Deprivation Index (TDI, continuous), and body mass index (BMI, continuous in kg/m2). TDI was measured as a surrogate for socioeconomic deprivation30. Lifestyle factors included smoking status (ever or never), current drinking status (current drinking or not), diabetes (with or without), and physical activities (low, moderate, or high). Physical activity was measured by the International Physical Activity Questionnaire (IPAQ). The detailed definition of covariates can be found in Table S1. The demographic information and laboratory data were collected from the hospital information system of the Third Xiangya Hospital, which included age, sex, BMI, smoking and drinking status, total amylase, amylopsin, glucose, leukocyte, and calcium. For the missing or ‘unknown’ covariate, median values were used for continuous variables, while the most frequent category was chosen for categorical variables. Animal study Chemicals and reagents L-arginine hydrochloride (LA, #A6969), sodium carboxymethyl cellulose, and hypoxanthine (HX, #H9377) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Potassium oxonate (PO, #HY-17511), Maesopsin (#HY-122812), 8-(3-Chlorostyryl) caffeine (CSC, #HY-103164 A), Rimonabant (#HY-14136), and Dimethyl Sulfoxide (DMSO, #HY-Y0320) were purchased from MedChemExpress (Monmouth Junction, NJ, USA). Cell Counting Kit-8 (CCK-8; #C6005) was purchased from NCM Biotech (Suzhou, China). Experiment design Male BALB/c mice weighing 20–25 g were purchased from Hunan Silex Jingda Laboratory Animal Co., Ltd. Male mice were exclusively employed in this study to minimize hormonal heterogeneity and ensure experimental consistency with established L-arginine-induced AP protocols, which is a widely adopted experimental design in initial mechanistic investigations of AP pathogenesis. Mice were housed in a specific pathogen-free (SPF) animal facility maintained at 23 ± 2 °C with relative humidity controlled at 44% and 52%. The mice were subjected to a 12-hour light-dark cycle and had ad libitum access to food and water throughout the study. Animal protocols were approved by the Animal Welfare Ethics Committee of the Xiangya School of Basic Medical Sciences, Central South University (approval number 2023-KT072). The work has been reported in accordance with the ARRIVE criteria31. Mice were randomly assigned to one of four experimental groups: (1) Control group (Ctrl); (2) HUA group; (3) AP group; and (4) HUA combined with AP group (HUA + AP). In the HUA group, mice received intraperitoneal injections of PO (400 mg/kg/day) for 14 days, along with oral gavage of HX (400 mg/kg/day) for 7 days32,33. Mice in the AP group were treated with two intraperitoneal injections of 8% L-arginine hydrochloride (pH 7.0, 4 g/kg body weight), administered twice at one-hour intervals34, on the 15th day of the study. Mice in the HUA + AP group received the same treatment as the HUA group, followed by the L-arginine hydrochloride injections as described for the AP group. Mice in the control group were administered an equivalent volume of vehicle solution composed of normal saline and sodium carboxymethyl cellulose. Animals were anesthetized with 2–3% isoflurane inhalation (in oxygen) before CO₂ asphyxia for euthanasia. Blood and tissue samples were collected at the indicated time points post-euthanasia. Serum was isolated from the blood samples following initial processing. The tissue samples (pancreas and lung) were immediately snap-frozen in liquid nitrogen and stored at -80 °C for further analysis. Histological examination The collected pancreatic and lung tissues were fixed in 4% paraformaldehyde, followed by sequential dehydration, and clearing before paraffin embedding. Section (5 μm thickness) were prepared and stained with hematoxylin and eosin (H&E) to evaluate tissue damage. The severity of lesions was scored by two pathologists using a modified Grewal scale35. Determination of serum biochemical indexes After collecting peripheral blood, the samples were centrifuged at room temperature at 300×g for 10 min. The resulting supernatants were collected for subsequent analysis. Serum amylase and uric acid were determined using commercially supplied kits (Cat. No. 105-000475-00 and 105-000476-00, Mindray, Shenzhen, China) on a Mindray automatic biochemical analyzer. Bulk RNA sequencing Total RNA was extracted from pancreatic tissue samples using TRIzol reagent (Invitrogen, CA, USA). RNA quality was assessed using the Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA) to ensure integrity and purity. Strand-specific RNA-seq libraries were prepared by Novogene Co., Ltd. (Beijing, China) following standard protocols. The clustering of index-coded samples was performed on the cBot Cluster Generation System using the TruSeq PE Cluster Kit v3-cBot-HS (Illumina, CA, USA) according to the manufacturer’s guidelines. PCR products were purified using the AMPure XP system (Beckman Coulter, CA, USA), and library quality was evaluated using the Agilent Bioanalyzer 2100 system. After cluster generation, the libraries were sequenced on the Illumina Novaseq platform, yielding 150 bp paired-end reads. Clean data (clean reads) were obtained by removing reads containing adapters, poly-N sequences, and low-quality reads from the raw data using in-house bioinformatics pipelines. The reference genome index was constructed using Hisat2 v2.0.5, and paired-end clean reads were aligned to the reference genome using the same software36. Differential expression analysis was conducted using DESeq2, with a threshold of |log2FC| > 1 and FDR-adjusted p ≤ 0.05 to identify differentially expressed genes (DEGs). Functional enrichment analysis of DEGs was performed using the clusterProfiler package in R 4.2.2, using annotations from the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases (www.kegg.jp/kegg/kegg1.html)37,38. All statistical analyses were executed in R 4.2.2. Metabolomics profiling Upon sacrifice, fresh fecal contents were immediately collected from the distal colon of each mouse. Each fecal sample was weighed at 50 mg for the metabolomics study. The metabolites were extracted using 500 µL pre-cooled methanol (containing 5 ppm 2-chlorophenylalanine). Through vortex, grind, ultrasonic, freeze, centrifuge, and filtrate, the filtrate was collected for the high-performance liquid chromatography-mass spectrometry (LC-MS) analysis. The chromatographic separation was achieved on an ACQUITY UPLC HSS T3 column (100Å, 1.8 μm, 2.1 mm × 100 mm). The Thermo Orbitrap Exploris 120 mass spectrometer was used to collect DDA mass spectrometric data in positive and negative ion modes under the control of Xcalibur software (version: 4.7, Thermo). The raw format data was imported into the commercial software Compound Discoverer™ 3.3 (version 3.3.2.31, Thermo, Waltham, USA). The identification of metabolites was based on a self-built library PSNGM Database, mzCloud online library (https://www.mzcloud.org/), LIPID MAPS (https://www.lipidmaps.org/), HMDB (https://hmdb.ca/), MoNA (https://mona.fiehnlab.ucdavis.edu/) and NIST_2020_MSMS spectral library. DNA Extraction and Shotgun Sequencing Mice fecal DNA was extracted using the OMEGA Mag-Bind Soil DNA Kit (M5635-02) (Omega Bio-Tek, Norcross, GA, USA). The quality and quantity of extracted DNA were measured by agarose gel electrophoresis and Qubit™ 4 Fluorometer, with WiFi: Q33238 (Qubit™ Assay Tubes: Q32856; Qubit™ 1X dsDNA HS Assay Kit: Q33231) (Invitrogen, USA), respectively. The qualified DNA was processed to construct the shotgun metagenomics sequencing libraries with insert sizes of ~ 400 bp by using Illumina TruSeq Nano DNA LT Library Preparation Kit (Illumina, USA). Each library was sequenced by the Illumina NovaSeq platform (Illumina, USA) with PE150 strategy at Personal Biotechnology Co., Ltd. (Shanghai, China)39. Bioinformatic processing was performed on quality-filtered reads (Cutadapt v1.2.1; fastp v0.23.2) following host genome subtraction (Minimap2)40,41. Taxonomic classification was executed using Kraken2 against the GTDB database. De novo assembly was conducted via Megahit (v1.1.2), followed by gene prediction using Prodigal (v2.6.3). A non-redundant gene catalog was established through mmseqs2 clustering (95% identity, 90% coverage). Gene abundances were calculated using Minimap2 and feature Counts. Functional annotations were assigned via Diamond or mmseqs2 search against KEGG (release 79), EggNOG (v4.5), and CAZy (available November 2018) databases, with additional pathway analysis performed using KOBAS and EggNOG-mapper42,43. To identify taxa and functional features with significant abundance differences between groups, we employed the Linear discriminant analysis effect size (LEfSe) method based on non-redundant gene profiles, adhering to the software’s default parameter settings44. Cell study Cell culture Rat pancreatic AR42J acinar cells and mouse immortalized bone marrow-derived macrophages (iBMDMs) were obtained from the American Type Culture Collection. AR42J cells were cultured in F12/Dulbecco’s Modified Eagle Medium (F12/DMEM, Basalmedia, Shanghai, China), while iBMDMs were cultured in DMEM (Gibco, Grand Island, NY, USA), supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin. Cells were maintained in a humidified incubator at 37 °C with 5% CO₂. Upon reaching confluence, the cells were trypsinized and resuspended in a fresh medium. All cell lines used in this study were confirmed to be mycoplasma-free. Cell viability assay Cell viability was evaluated using the CCK-8 assay45. Pancreatic AR42J acinar cells were seeded in 96-well plates at a density of 1 × 104 cells per well. After treatment, 100 µL of fresh medium and 10 µL of CCK-8 solution were added to each well. The plates were then incubated for 2 h at 37 °C in a humidified incubator with 5% CO₂. Absorbance was measured at 450 nm using a microplate reader (BioTek, Winooski, VT, USA). Cell viability was calculated by normalizing the absorbance of the control cells to 100% viability. Uric acid multi-concentration configuration Twenty milligrams of uric acid were dissolved in one milliliter of 1 M sodium hydroxide to create a stock solution at a concentration of 20 mg/mL (120 mM), which was then sterilized by filtration. F12/DMEM medium with 10% fetal bovine serum (FBS) was added to the stock solution and serially diluted to concentrations such as 0.3 mM, 0.6 mM, 1.2 mM, and 2.4 mM46. A control group with medium only was also established. The pH of all solutions was adjusted to neutral, and they were filtered again for sterility. Preparation of conditioned medium (CM) Pancreatic AR42J acinar cells were plated into 10-cm dishes and treated with or without 10 mg/mL L-arginine and 2.4 mM uric acid. The culture media collected from these treatments were designated as Ctrl-AR42J-CM or LA/U-AR42J-CM. These media were collected at the indicated time points, filtered through 0.22-µm filters for sterilization, and then stored at -80 °C for future use. Quantitative reverse transcription-polymerase chain reaction (qPCR) RNA was isolated from pancreatic tissue, pancreatic AR42J acinar cells, and iBMDMs using TRIzol® Reagent (#AG21101, Accurate Biotechnology, Changsha, China) according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized from total RNA using the PrimeScript® RT reagent Kit and gDNA Eraser kit (#AG11728, Accurate Biotechnology, Changsha, China). The synthesized cDNAs were diluted and subjected to qPCR analysis using an SYBR® Green Quantitative PCR kit (#AG11701, Accurate Biotechnology, Changsha, China). Relative changes in gene expression were calculated using the 2-△△Ct method and normalized to 18s rRNA. The mRNA levels were expressed as relative values in arbitrary units (AU), with the control group set to 1. The PCR primers used in this study were designed using Primer 5.0 online software and synthesized by TSINGKE (Changsha, China). The sequences of the primers are listed in Table S8. Statistical analyses In the human study, baseline characteristics of participants were presented as mean ± standard deviation (SD) for continuous variables and numbers (percentages) for categorical variables according to the groups of uric acid concentration. In the prospective cohort study, Cox proportional hazards regression analysis was performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). We constructed three multivariable models to conduct a stepwise regression: (1) model 1 was adjusted for age, sex, ethnicity, education, and TDI; (2) further adjusted for BMI, alcohol consumption status, smoking status, and physical activity based on model 1; (3) model 3 was further adjusted for diabetes based on model 2. Schoenfeld residuals were employed to verify the proportional hazards assumption, and the proportionality assumption was not violated. In the subgroup analyses, we assessed the association between uric acid and the risk of onset of AP stratified by the covariates mentioned above. To verify the robustness of the results, several sensitivity analyses were performed based on model 3: (1) additionally adjusting for C-reactive protein (CRP); (2) additionally adjusting for gout; (3) additionally adjusting for treatments with colchicine or uric acid-lowering medications; (4) additionally adjusting for creatinine; (5) excluding participants with incident AP within first one, two, or three years of follow-up, respectively. Matching was performed by sex and age using the R package MatchIt. Conditional logistic regression analysis calculated odds ratios (OR) and 95% CIs for the relationship between uric acid and the severity of AP. The prediction performance of uric acid and other indices was measured by the receiver operating characteristic (ROC) and the areas under the curve (AUC). The two-sided p-value < 0.05 was considered statistically significant. The statistical analyses were performed using R 4.3.3. For animal study and cell study, statistical analyses were performed using GraphPad Prism 9.5.1 software (GraphPad Software Inc., San Diego, CA, USA). Data are presented as means ± SD. All datasets met the assumptions required for the statistical tests, including normal distribution. Comparisons of mean values between the two groups were performed using an unpaired Student’s t-test. For comparisons among three or more groups, analysis of variance (ANOVA) was employed. If significant differences were detected by ANOVA, Tukey’s post hoc test was applied for pairwise comparisons. Survival rates were compared between groups using the log-rank test. A two-tailed p-value < 0.05 was considered statistically significant. Results Uric acid and incident acute pancreatitis To assess the association between serum uric acid concentration and the risk of developing AP, we analyzed data from 467,859 participants in the UK Biobank. Individuals with a prior history of AP at baseline or missing serum uric acid measurements were excluded (Fig. 1A). Fig. 1Study design and basic characteristics in UK Biobank. (A) Study design and the association between urate and the risk of onset acute pancreatitis. (B) Baseline characteristics of participants across the level of serum urate in UK Biobank (N = 467,859). Study design and basic characteristics in UK Biobank. (A) Study design and the association between urate and the risk of onset acute pancreatitis. (B) Baseline characteristics of participants across the level of serum urate in UK Biobank (N = 467,859). Baseline characteristics of the study population are summarized in Fig. 1B and Table S2. Participants in the highest quartile of serum uric acid were more likely to be male, older, current smokers and alcohol consumers, have diabetes, a higher BMI, higher TDI, and lower levels of physical activity compared to those in the lowest quartile. During a median follow-up of 13.69 years, a total of 2,815 incident AP cases were documented. After adjusting for potential confounders, Cox proportional hazards regression analysis demonstrated that individuals in the highest uric acid quartile (Q4) had a significantly increased risk of developing AP compared to those in the lowest quartile (Q1), with an HR of 1.25 (95% CI: 1.10–1.43; p for trend < 0.001). When serum uric acid was treated as a continuous variable, each standard deviation (SD) increase in uric acid level was associated with a 12% higher risk of AP (HR = 1.12, 95% CI: 1.07–1.17) (Fig. 1A, Table S3). Subgroup analyses revealed significant interactions between the serum uric acid concentration and AP incidence across sex (p = 0.016 for interaction), education (p = 0.012 for interaction), BMI (p = 0.004 for interaction), and diabetes status (p < 0.001 for interaction) (Figure S1). Notably, elevated uric acid levels were more strongly associated with increased AP risk among females, individuals without a college education, and those without diabetes. Sensitivity analyses revealed that the relationship between uric acid levels and AP risk remained consistent even after adjusting for additional variables, including CRP, gout, creatinine, and treatments with colchicine or uric acid-lowering medications (Table S6). Furthermore, exclusion of participants who developed AP within the first one, two, or three years of follow-up did not materially alter the results (Table S7). Uric acid and the severity of acute pancreatitis To further evaluate the correlation between uric acid levels and the AP severity, we retrospectively collected clinical and biochemical data from 342 patients diagnosed with AP at the Third Xiangya Hospital in Changsha, China, comprising 171 patients with MAP and 171 with SAP. The mean (± SD) ages for the MAP and SAP groups were 45.94 ± 14.42 and 45.45 ± 14.83 years, respectively. Compared to the MAP group, patients in the SAP group exhibited significantly elevated levels of total amylase, amylopsin, leukocyte count, and uric acid, along with significantly lower serum calcium levels (p < 0.05). No statistically significant differences were observed between the two groups regarding BMI, smoking status, or alcohol consumption (p > 0.05) (Table S4). The association between uric acid levels and the severity of AP was further assessed using conditional logistic regression (Fig. 2A, Table S5). Individuals with elevated uric acid levels had an increased risk of SAP, with an unadjusted OR of 2.64 (95% CI: 1.64–4.18). After adjusting for potential confounders, the OR remained significant at 2.43 (95% CI: 1.08–5.48). Fig. 2Study design and the receiver operating characteristic curve in the Third Xiangya Hospital cohort. A. Third Xiangya Hospital cohort and the association between serum urate and the severity of acute pancreatitis. B. Serum uric acid level in MAP cases and SAP cases. ***p < 0.001, using Student’s t-test. C. Receiver operating characteristic curves of amylopsin, leukocyte, glucose, uric acid, and calcium for predicting the severity of acute pancreatitis. Abbreviations: MAP, mild acute pancreatitis; SAP, severe acute pancreatitis. Study design and the receiver operating characteristic curve in the Third Xiangya Hospital cohort. A. Third Xiangya Hospital cohort and the association between serum urate and the severity of acute pancreatitis. B. Serum uric acid level in MAP cases and SAP cases. ***p < 0.001, using Student’s t-test. C. Receiver operating characteristic curves of amylopsin, leukocyte, glucose, uric acid, and calcium for predicting the severity of acute pancreatitis. Abbreviations: MAP, mild acute pancreatitis; SAP, severe acute pancreatitis. ROC analysis demonstrated the discriminatory capacity of various biomarkers for predicting AP severity. The AUCs for amylopsin, leukocyte count, glucose, uric acid, and calcium were 0.5853, 0.5921, 0.6496, 0.7693, and 0.8958, respectively. Notably, the combination of uric acid and calcium yielded the highest predictive performance, with an AUC of 0.9504 (Fig. 2C), indicating strong potential as a composite biomarker for AP severity. Pearson correlation analysis showed no significant linear correlations between uric acid and the individual biochemical indices mentioned above (Figure S2), suggesting that uric acid contributes to AP severity through mechanisms independent of these parameters. Hyperuricemia exacerbates acute pancreatitis in mice To investigate the impact of HUA on the pathogenesis of AP, we established a murine model of HUA by administering PO and HX. Building on this model, L-arginine was used to induce AP following established protocols47. Serum uric acid levels were elevated in the AP, HUA, and HUA + AP groups compared to controls, with the HUA + AP group displaying the highest levels (Fig. 3A). Notably, HUA significantly increased the mortality rate in AP mice (Fig. 3B). Fig. 3Hyperuricemia aggravates acute pancreatitis in mice. A. The serum levels of uric acid were measured at 48 h after the second L-arginine administration (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). B. The Kaplan-Meier survival curves were monitored for 72 h following the first injection of L-arginine (Ctrl, n = 16; AP, n = 16; HUA, n = 16; HUA + AP, n = 16). C. Pancreatic sections were stained with H&E at 48 h after the second L-arginine administration. Scale bar = 100 μm. D. Accordingly, pancreatic pathology was scored (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). E. The serum levels of amylase were measured at 48 h after the second L-arginine administration (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). F. Lung sections were stained with H&E at 48 h after the second L-arginine administration. Scale bar = 100 μm. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; H&E, hematoxylin and eosin. Hyperuricemia aggravates acute pancreatitis in mice. A. The serum levels of uric acid were measured at 48 h after the second L-arginine administration (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). B. The Kaplan-Meier survival curves were monitored for 72 h following the first injection of L-arginine (Ctrl, n = 16; AP, n = 16; HUA, n = 16; HUA + AP, n = 16). C. Pancreatic sections were stained with H&E at 48 h after the second L-arginine administration. Scale bar = 100 μm. D. Accordingly, pancreatic pathology was scored (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). E. The serum levels of amylase were measured at 48 h after the second L-arginine administration (Ctrl, n = 5; AP, n = 5; HUA, n = 5; HUA + AP, n = 5). F. Lung sections were stained with H&E at 48 h after the second L-arginine administration. Scale bar = 100 μm. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; H&E, hematoxylin and eosin. Histopathological examination of pancreatic tissue revealed that mice in the HUA + AP group exhibited more extensive leukocyte infiltration, acinar cell necrosis, and interstitial edema compared to those with AP alone (Fig. 3C and D). Consistent with these findings, serum amylase levels—a clinical biomarker for pancreatic injury—were higher in the HUA + AP group relative to the AP group (Fig. 3E). Given that severe AP is frequently associated with acute lung injury (ALI), we also assessed lung pathology. ALI was markedly exacerbated in the HUA + AP group compared to the AP group, indicating increased systemic inflammation and multi-organ involvement (Fig. 3F). CNR1 mediated retrograde endocannabinoid signaling pathway is associated with hyperuricemia-exacerbated acute pancreatitis To elucidate the underlying mechanisms by which HUA exacerbates AP, we performed RNA sequencing on pancreatic tissues from control and AP mice with or without HUA. Differentially expressed genes (DEGs) regulated by HUA were visualized using volcano plots (Fig. 4A). A Venn diagram analysis identified three genes —Cnr1, Hist1h3d, and Klk1b26 —that were consistently upregulated in response to HUA in both control and AP groups (Fig. 4B). Fig. 4Screening of key signaling pathways and target genes involved in the exacerbation of acute pancreatitis induced by hyperuricemia. A. Volcano plots from RNA sequencing data represent DEGs between the HUA group and the Ctrl group, as well as between the HUA + AP group and the AP group. B. The Venn diagram depicts the intersection of common upregulated DEGs identified in the comparisons between the HUA vs. Ctrl and HUA + AP vs. AP groups. C. qPCR analysis of Cnr1, Hist1h3d, and Klk1b26 mRNA levels in the pancreatic tissue of mice. D. KEGG pathway enrichment analysis of DEGs from RNA sequencing data in the HUA and HUA + AP groups. The top 10 pathways from the KEGG enrichment analysis are ranked by p-adjvalue (left) and gene counts (right), presented as bar charts. E. The heatmap shows the DEGs related to retrograde endocannabinoid signaling (left) and carbon metabolism (right) identified from RNA sequencing data in HUA and HUA + AP group (n = 4 biologically independent samples). Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; DEGs, differentially expressed genes. Screening of key signaling pathways and target genes involved in the exacerbation of acute pancreatitis induced by hyperuricemia. A. Volcano plots from RNA sequencing data represent DEGs between the HUA group and the Ctrl group, as well as between the HUA + AP group and the AP group. B. The Venn diagram depicts the intersection of common upregulated DEGs identified in the comparisons between the HUA vs. Ctrl and HUA + AP vs. AP groups. C. qPCR analysis of Cnr1, Hist1h3d, and Klk1b26 mRNA levels in the pancreatic tissue of mice. D. KEGG pathway enrichment analysis of DEGs from RNA sequencing data in the HUA and HUA + AP groups. The top 10 pathways from the KEGG enrichment analysis are ranked by p-adjvalue (left) and gene counts (right), presented as bar charts. E. The heatmap shows the DEGs related to retrograde endocannabinoid signaling (left) and carbon metabolism (right) identified from RNA sequencing data in HUA and HUA + AP group (n = 4 biologically independent samples). Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; DEGs, differentially expressed genes. To validate these findings, we measured mRNA expression levels of the three candidate genes in pancreatic tissues using quantitative PCR (qPCR). Among them, only Cnr1 was significantly upregulated in response to HUA (Fig. 4C), suggesting a potential role for CNR1 in mediating the effects of HUA on AP. To further explore the biological pathways involved, we conducted the KEGG pathway enrichment analysis. The top 10 pathways upregulated by HUA in AP mice were identified based on p-values and gene counts. Notably, retrograde endocannabinoid signaling and carbon metabolism emerged as the most significantly enriched pathways (Fig. 4D). Within the retrograde endocannabinoid (eCB) signaling pathway, Cnr1 was the most significantly upregulated gene, based on both p-value and log₂ fold change (Fig. 4E). Given its consistent upregulation and prominent role within the eCB signaling pathway, we hypothesize that the CNR1-mediated retrograde eCB signaling plays a central role in the exacerbation of AP by HUA. These findings suggest that CNR1 may serve as a key mediator linking elevated uric acid levels to enhanced inflammatory and pathological responses in AP, thereby highlighting cannabinoid receptor signaling as a potential therapeutic target in this context. CNR1 mediates inflammatory responses in uric acid-aggravated acute pancreatitis To elucidate the precise role of CNR1 in HUA-associated AP, we established an in vitro model using pancreatic AR42J acinar cells. Based on our previous findings that 10 mg/mL L-arginine induces cell death in AR42J cells48, we treated cells with various concentrations of uric acid in combination with 10 mg/mL L-arginine. Uric acid pretreatment caused a dose-dependent reduction in cell viability, with the greatest decrease observed in cells co-treated with 10 mg/mL L-arginine and 2.4 mM uric acid (Fig. 5A). Conversely, rimonabant, a classic CNR1 antagonist, failed to restore cell viability of AR42J cells exposed to L-arginine and high uric acid levels (Fig. 5B), suggesting that CNR1 may not directly modulate acinar cell survival under these conditions. Fig. 5CNR1 is associated the exacerbation of inflammatory responses in acute pancreatitis induced by high levels of uric acid. A. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and different doses of uric acid was assessed using the CCK-8 assay. B. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of Rimonabant was determined by CCK-8 assay. C. Cell viability of iBMDMs treated with conditioned medium from AR42J cells for 3–24 h was assessed using the CCK-8 assay. LA/U-AR42J-CM was collected from the supernatant of AR42J cells stimulated with L-arginine (10 mg/mL) and uric acid (2.4 mM) for 24 h. Ctrl-AR42J-CM was collected from the supernatant of untreated pancreatic AR42J acinar cells. D. Cell viability of iBMDMs treated with conditioned medium from AR42J cells was assessed in the absence or presence of different doses of Rimonabant for 12 h using the CCK-8 assay. E-G. qPCR analysis of Il1b, Il6, and Il10 mRNA levels in iBMDMs treated with conditioned medium from AR42J cells in the absence or presence of Rimonabant (100 µM) for 12 h. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. Abbreviations: AP, acute pancreatitis. CNR1 is associated the exacerbation of inflammatory responses in acute pancreatitis induced by high levels of uric acid. A. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and different doses of uric acid was assessed using the CCK-8 assay. B. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of Rimonabant was determined by CCK-8 assay. C. Cell viability of iBMDMs treated with conditioned medium from AR42J cells for 3–24 h was assessed using the CCK-8 assay. LA/U-AR42J-CM was collected from the supernatant of AR42J cells stimulated with L-arginine (10 mg/mL) and uric acid (2.4 mM) for 24 h. Ctrl-AR42J-CM was collected from the supernatant of untreated pancreatic AR42J acinar cells. D. Cell viability of iBMDMs treated with conditioned medium from AR42J cells was assessed in the absence or presence of different doses of Rimonabant for 12 h using the CCK-8 assay. E-G. qPCR analysis of Il1b, Il6, and Il10 mRNA levels in iBMDMs treated with conditioned medium from AR42J cells in the absence or presence of Rimonabant (100 µM) for 12 h. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. Abbreviations: AP, acute pancreatitis. Given that AP is initiated by acinar cell injury, which leads to the release of damage-associated molecular patterns (DAMPs) that recruit immune cells and amplify systemic inflammation49–53, we next investigated the impact of acinar cell-derived signals on macrophage responses. CM from AR42J cells treated with L-arginine and uric acid was used to stimulate iBMDMs. CM exposure led to a time-dependent reduction in macrophage viability, which was partially reversed by pretreatment with 100 µM rimonabant (Fig. 5C and D). Moreover, rimonabant treatment showed a tendency to reduce the mRNA expression of pro-inflammatory cytokines, such as IL-1β and IL-6, whereas slightly increasing the mRNA expression of the anti-inflammatory cytokine IL-10 (Fig. 5E and G). Altogether, these findings suggest that CNR1 may play a modulatory role in macrophage activation during HUA-exacerbated AP, rather than directly affecting acinar cell viability. The gut metabolite maesopsin attenuates the inflammatory response in uric acid-aggravated acute pancreatitis To assess the potential role of gut-derived metabolites in modulating AP severity, we performed non-targeted metabolomic profiling on fecal samples from experimental groups. Among the detected compounds, six metabolites—maesopsin, Caylin-2, melitidin, N-methyl-D-aspartic acid, ADMDM-Chromenol, and 7-DMHA-Chromenide—were significantly elevated in AP mice and further increased in the presence of HUA (Fig. 6A). Conversely, caffeine was the only metabolite significantly reduced in AP and further decreased by HUA (Fig. 6B). Among these six overlapping metabolites, maesopsin was selected for initial functional evaluation based on its fold change analysis (Fig. 6C), consistent elevation across disease states and the availability of purified compound. Fig. 6Intestinal metabolite Maesopsin inhibits inflammatory response induced by high levels of uric acid and L-arginine. A-B. The Venn diagram illustrates the overlap of significantly elevated (A) and decreased (B) metabolites (NEG mode) among four groups: HUA + AP vs. AP (Red), AP vs. Ctrl (Green), HUA + AP vs. HUA (Purple), and HUA vs. Ctrl (Blue). Metabolites were identified with a significance threshold of p < 0.05. Numbers in overlapping regions indicate shared metabolites between groups, while unique metabolites specific to each group are labeled in non-overlapping areas. *Abbreviation: ADMDM-Chromenol, 1,5-Anhydro-6-deoxy-2-O-(6-deoxy-.alpha.-L-mannopyranosyl)-1-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4 H-chromen-6-yl)hexitol; 7-DMHA-Chromenide, 7-((6-Deoxy-.alpha.-L-mannopyranosyl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4 H-chromen-3-yl 3-O-acetyl-6-deoxy-.alpha.-L-mannopyranoside. C. The heat map shows the fold changes of six differentially upregulated metabolites across the different groups. D. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of Maesopsin was determined by CCK-8 assay. E. Cell viability of iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells was assessed in the absence or presence of different doses of Maesopsin for 12 h using the CCK-8 assay. F. qPCR analysis of Cnr1 mRNA levels in iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells in the absence or presence of different doses of Maesopsin for 12 h. G-I. qPCR analysis of Il1b, Il6, and Il10 mRNA levels in iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells in the absence or presence of Maesopsin (0.1 µM) for 12 h. J. Cell viability of pancreatic AR42J acinar cells treated with different concentrations of CSC for 24 h was assessed by CCK-8 assay. K. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of CSC was determined by CCK-8 assay. L. Cell viability of iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells was assessed in the absence or presence of different doses of CSC for 12 h using the CCK-8 assay. M. Integrated multi-omics workflow for investigating the mechanisms of HUA-aggravated AP. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; CSC, caffeine. Intestinal metabolite Maesopsin inhibits inflammatory response induced by high levels of uric acid and L-arginine. A-B. The Venn diagram illustrates the overlap of significantly elevated (A) and decreased (B) metabolites (NEG mode) among four groups: HUA + AP vs. AP (Red), AP vs. Ctrl (Green), HUA + AP vs. HUA (Purple), and HUA vs. Ctrl (Blue). Metabolites were identified with a significance threshold of p < 0.05. Numbers in overlapping regions indicate shared metabolites between groups, while unique metabolites specific to each group are labeled in non-overlapping areas. *Abbreviation: ADMDM-Chromenol, 1,5-Anhydro-6-deoxy-2-O-(6-deoxy-.alpha.-L-mannopyranosyl)-1-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4 H-chromen-6-yl)hexitol; 7-DMHA-Chromenide, 7-((6-Deoxy-.alpha.-L-mannopyranosyl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4 H-chromen-3-yl 3-O-acetyl-6-deoxy-.alpha.-L-mannopyranoside. C. The heat map shows the fold changes of six differentially upregulated metabolites across the different groups. D. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of Maesopsin was determined by CCK-8 assay. E. Cell viability of iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells was assessed in the absence or presence of different doses of Maesopsin for 12 h using the CCK-8 assay. F. qPCR analysis of Cnr1 mRNA levels in iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells in the absence or presence of different doses of Maesopsin for 12 h. G-I. qPCR analysis of Il1b, Il6, and Il10 mRNA levels in iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells in the absence or presence of Maesopsin (0.1 µM) for 12 h. J. Cell viability of pancreatic AR42J acinar cells treated with different concentrations of CSC for 24 h was assessed by CCK-8 assay. K. Cell viability of pancreatic AR42J acinar cells treated with L-arginine (10 mg/mL) and uric acid (2.4 mM) in the absence or presence of different doses of CSC was determined by CCK-8 assay. L. Cell viability of iBMDMs treated with conditioned medium from pancreatic AR42J acinar cells was assessed in the absence or presence of different doses of CSC for 12 h using the CCK-8 assay. M. Integrated multi-omics workflow for investigating the mechanisms of HUA-aggravated AP. Data are presented as mean ± SD. Statistical comparisons were performed using one-way ANOVA with Tukey’s multiple comparisons test. p < 0.05 was considered statistically significant. Abbreviations: HUA, hyperuricemia; AP, acute pancreatitis; CSC, caffeine. Maesopsin had no significant effect on the viability of AR42J pancreatic acinar cells treated with L-arginine and elevated uric acid (Fig. 6D). However, in iBMDMs stimulated with CM from AR42J cells exposed to L-arginine and uric acid (LA/U-AR42J-CM), low concentrations of maesopsin significantly restored macrophage viability (Fig. 6E). Furthermore, maesopsin treatment reduced mRNA expression of Cnr1 and pro-inflammatory cytokines IL-1β and IL-6, while increasing expression of the anti-inflammatory cytokine IL-10 (Fig. 6F and I). To compare its effects with other compounds, we examined (E)-8-(3-Chlorostyryl) caffeine (CSC), a derivative of caffeine. CSC exhibited no cytotoxicity in AR42J cells or iBMDMs at concentrations ranging from 0.1 to 50 µM (Fig. 6J). However, CSC failed to rescue either cell type from the damage induced by L-arginine and uric acid (Fig. 6K and L). Together, these findings suggest that the gut metabolite maesopsin exerts anti-inflammatory effects during HUA-exacerbated AP by suppressing CNR1 expression and modulating cytokine profiles. Maesopsin and the gut microbiota Given the close interplay between fecal metabolites and gut microbial composition, we next explored the potential relationship between maesopsin and specific gut microbiota to gain mechanistic insights into the gut ecosystem. Spearman’s correlation analysis revealed a strong positive association between maesopsin levels and the abundance of Limosilactobacillus reuteri D (Figure S3A). Interestingly, the genus Limosilactobacillus, which has been recognized as a promising probiotic54, was significantly enriched in the HUA + AP group (Figure S 3B). This enrichment, along with the strong correlation with maesopsin, suggests that Limosilactobacillus may contribute to the production or modulation of maesopsin and play a protective role in the gut–pancreas axis during uric acid–exacerbated AP. Discussion Elevated serum uric acid has emerged as a risk factor for a range of metabolic disorders, including hypertension, cardiovascular disease, and chronic kidney disease8,55–58. Recent studies have also suggested a potential link between HUA and AP16,59, yet the mechanistic basis for this association has remained unclear. In this study, we demonstrated an association between elevated serum uric acid levels and AP onset in a large UK Biobank cohort, consistent with findings from the Kailuan cohort in China60. We further constructed a systematic and cohesive analytical framework integrating pancreatic transcriptomics, fecal metabolomics, and gut microbiome profiling, which clarified the sequential crosstalk and regulatory relationships across these three omics datasets. Each omics layer identified characteristic key molecules (CNR1 from transcriptomics, maesopsin from metabolomics, Limosilactobacillus reuteri D from the microbiome) and delineated their regulatory effects on the pathological processes of HUA-exacerbated AP. This integrative approach renders the interrelationships and synergistic regulatory mechanisms underlying the multi-omics data more explicit and convincing. Notably, our study advances the epidemiological investigation of the uric acid-AP association with three novel contributions: cross-ethnic validation of this association in an independent Chinese clinical cohort, the development of a high-performance uric acid-calcium composite model for AP severity prediction with enhanced clinical utility, and in-depth mechanistic insights into the gut-pancreas axis via integrated multi-omics analysis and preclinical validation—an essential exploration absent from prior pure epidemiological research. Collectively, these findings provide novel clinical application value and a deeper mechanistic understanding that extends beyond existing literature in the field. Current biomarkers for predicting AP severity, including C-reactive protein, procalcitonin, and radiologic imaging, are limited by delayed response, invasiveness, cost, and limited accessibility61. In our analysis, ROC curve evaluation revealed that uric acid alone had moderate predictive value, and when combined with serum calcium levels, given the frequent occurrence of hypocalcemia in severe AP62, the predictive accuracy for AP severity was substantially improved. These findings suggest that uric acid, particularly in combination with calcium, could serve as a practical biomarker for assessing disease severity and prognosis. Crucially, this profile is intended to complement, rather than replace, established clinical frameworks. To ensure its diagnostic reliability, these findings require further validation through large-scale, prospective, multicenter cohort studies before clinical implementation. Emerging studies observed that dysregulated purine metabolism is associated with AP progression. Elevated serum phosphate levels and xanthine oxidase (XO) activity have been linked to AP severity, implicating the extracellular purinergic system in systemic inflammatory responses63,64. XO catalyzes the production of uric acid and is upregulated in both preclinical and clinical models of severe AP. Pharmacologic inhibition of XO protects against AP by modulating hypoxia-inducible factor-1α (HIF-1α)-regulated lactate dehydrogenase A (LDHA) and NLR family pyrin domain containing 3 (NLRP3) inflammasome signaling65. Despite these insights, the role of uric acid—the final product of this pathway—has received comparatively little attention. We revealed that HUA exacerbated AP in mice, as evidenced by worsened pancreatic histopathology, elevated serum amylase, multi-organ dysfunction, and increased mortality (Fig. 3). Uric acid can activate pro-inflammatory pathways through interactions with toll-like receptors and by promoting oxidative stress, inducible nitric oxide synthase (iNOS) expression, and nitric oxide production in pancreatic β-cells8,66. These findings suggest that uric acid acts not only as a biomarker but also as an active mediator of inflammation and tissue injury. Our study supports this view and further demonstrates that uric acid-lowering agents, such as allopurinol, oxypurinol, and febuxostat, which have shown efficacy in experimental models of necrotizing AP64,65, may hold therapeutic potential in this context. To elucidate the underlying molecular mechanisms, we performed transcriptomic analysis of pancreatic tissue and identified Cnr1, which encodes CB1R, as a key gene upregulated by HUA in AP. KEGG pathway analysis highlighted enrichment of the eCB signaling pathway (Fig. 4D). As a member of the G-protein-coupled receptor family, CNR1 is a key component of the eCB system67. Recent studies have emphasized the involvement of CNR1 in various inflammation-related diseases68–70. The eCB system, which comprises CB1R and CB2R, endogenous ligands such as anandamide and 2-arachidonoylglycerol, and associated metabolic enzymes, is involved in neuronal, metabolic, and immune regulation71,72. Although CB2R has been extensively studied in immune cells, increasing evidence points to a role for CB1R in AP73,74. Consistent with these reports, we found that Cnr1 expression was upregulated in the HUA + AP group, indicating that CNR1 may mediate uric acid-driven inflammatory amplification in AP (Fig. 4C). Activation of CB1R worsens cerulein-induced AP, whereas its inhibition attenuates AP severity in sodium taurocholate and high-fat diet models75–77. Our in vitro findings revealed that uric acid enhanced L-arginine-induced acinar cell death and promoted macrophage-mediated inflammatory responses. Importantly, rimonabant–a CB1R antagonist–restored macrophage viability and reduced pro-inflammatory cytokine expression, although it did not protect acinar cells directly (Fig. 5). These results suggest that CNR1 promotes macrophage-driven inflammation in AP and may represent a viable therapeutic target. However, current CB1R antagonists are limited by central nervous system-related adverse effects78–80, underscoring the need for safer, tissue-specific inhibitors. Beyond host signaling pathways, our study also highlights the involvement of the gut microbiota in modulating the AP response. Metabolomic profiling of fecal samples identified maesopsin as significantly elevated in the HUA + AP group. Although maesopsin did not affect acinar cell viability, it restored macrophage viability, downregulated Cnr1, and suppressed IL-1β and IL-6 expression while promoting IL-10 expression (Fig. 6). These data suggest that maesopsin may counterbalance the inflammatory response induced by uric acid, possibly as a compensatory mechanism. Correlation analysis revealed a strong association between maesopsin and Limosilactobacillus reuteri D, a strain enriched in the HUA + AP group (Figure S3A-B). Prior studies have reported that Limosilactobacillus can reduce uric acid levels and ameliorate oxidative stress and inflammatory markers associated with HUA81–84. The observed enrichment of Limosilactobacillus in our model suggests that it contributes to the biotransformation or regulation of maesopsin, providing a potential link between microbial ecology and host inflammation. These findings support the therapeutic potential of microbiota–targeted interventions, including Limosilactobacillus–based probiotics, for mitigating AP severity in patients with hyperuricemia. Our findings carry meaningful translation value for AP clinical management, especially when combined with current framework like the revised Atlanta Classificaiton. The identified uric acid-calcium composite biomarker is designed to complement, not replace, established severity scores such as the Ranson criteria and APACHE II. Its clinical application for risk stratification and severity prediction requires further validation in large-scale, prospective, multicenter clinical cohorts to confirm its reliability and generalizability across diverse patient populations. Despite these promising insights, our study has several limitations. First, detailed data on dietary purine intake was lacking in human cohorts, which may act as a confounder factor affecting serum uric acid levels and the pathogenesis of AP. Future research will incorporate large-scale, prospective, multicenter clinical cohorts, and integrate standardized dietary questionnaires to control for these confounders, thereby validating the uric acid-calcium composite biomarker across diverse patient populations. Second, while male mice were exclusively used to minimize hormonal heterogeneity and ensure consistency with established AP protocols, this approach limits the generalizability of our findings to female populations. Future research will include both male and female mice to validate our core findings and explore potential sex-specific biological differences in the pathogenesis of HUA-exacerbated AP and its therapeutic response. Third, although our integrated multi-omics design provides novel mechanistic insights into HUA-exacerbated AP, the lack of robust in vivo mechanistic validation, particularly genetic and pharmacological validation of CNR1 and other key molecules identified by multi-omics—restricts the translational impact of our findings. Given that CNR1 was identified as a probable mediator of uric acid–induced inflammation, its precise downstream signaling mechanisms remain to be fully elucidated. Furthermore, in this study, no dose-response experiments were conducted for the CNR1 inhibitor rimantadine; therefore, further research on full-dose response analysis is needed to confirm the specificity of this effect. Follow-up biological experiments will focus on addressing this gap to provide a more comprehensive understanding of the gut-pancreas axis in HUA-exacerbated AP. Additionally, the study lacks in vivo genetic validation (e.g., knockout/knockdown) of key genes including Cnr1 and other DEGs, which limits the mechanistic depth of the identified signaling pathways. To address this critical gap, our ongoing follow-up research will conduct comprehensive functional validations of these genes via rigorously designed in vitro and in vivo experiments, aiming to fully elucidate their causal regulatory roles and downstream signaling cascades in HUA-exacerbated AP. This work will serve as the core focus of our subsequent studies to further refine the mechanistic framework of HUA-mediated pancreatic injury. Furthermore, the absence of interventional microbiome manipulation limits the confirmation of a causal relationship between gut microbiota, maesopsin, and AP severity. Future research incorporating targeted microbial interventions and larger clinical cohorts is therefore essential to validate the interaction and clarify its therapeutic relevance. Conclusions In summary, elevated uric acid contributes to AP onset and severity via CNR1-mediated endocannabinoid signaling and macrophage-driven inflammation. Concurrently, gut microbiota changes, notably increased Limosilactobacillus and the metabolite maesopsin, may provide compensatory anti-inflammatory effects. Thus, strategies targeting both uric acid metabolism and gut microbiota hold promise for improving AP outcomes. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1